Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
Diabetes drugs show heart protection in cancer patients receiving damaging chemotherapy, suggesting a dual benefit strategy.
GLP-1 and GIP/GLP-1 agonists show consistent cardioprotective effects (LV EF improvement ~7-20%) in chronic doxorubicin rodent models via anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms; no eligible human studies found. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- systematic review (PRISMA 2020, 13 rodent studies, no human studies identified)
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Cardiovasc Toxicol
Why it surfaced
Timely systematic review of GLP-1 agonist cardioprotection from doxorubicin cardiotoxicity—a clinically urgent question given GLP-1 drug class expansion and cancer-cardiology overlap—though evidence remains exclusively preclinical.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.